US NCI’s Gravitt On Stepping Up Cancer Control Efforts In Asia-Pacific

Dr Patti Gravitt, Deputy Director, Center for Global Health, US National Cancer Institute, in an interview with Scrip, discusses a range of strategies underway and proposed to strengthen cancer control efforts in the Asia Pacific. HPV vaccination and a regional cancer control dashboard are among the areas she highlighted.

APEC member economies up cancer control efforts • Source: Shutterstock

“It's of no use really for people to survive early childhood infectious diseases just to die prematurely of cancer,” observed a senior executive of the US National Cancer Institute (NCI) underscoring the need for continued international co-operation to strengthen cancer control policy programs as countries in the diverse Asia-Pacific region manage competing healthcare priorities.

In an interview with Scrip, Dr Patti Gravitt, Deputy Director, Center for Global Health, NCI, noted that several APEC [Asia-Pacific Economic Cooperation] member countries were still battling infectious disease burdens that are disproportionate to other world regions alongside an uptick in non-communicable diseases and outlined various

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

05 May 2025

• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

05 May 2025

• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

02 May 2025

• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

01 May 2025

• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.